文献速递免疫规划传染病防控与疫情报告

新冠疫苗基础-加强接种的安全性及有效性:BBIBP-CorV基础免疫者同源BBIBP-CorV与异源BNT162b2加强接种的比较

Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals.
PubMed 文献 · Vaccine · 2023-01-23

在巴林开展的非随机、非盲II期观察性社区试验,305名已完成两剂BBIBP-CorV基础免疫者分别接受同源BBIBP-CorV或异源BNT162b2加强接种。异源组抗S抗原抗体和中和抗体平均增幅显著高于同源组,同源组抗N抗原抗体显著升高,异源组非严重不良事件更常见但无严重不良事件。

要点

  • 异源BNT162b2加强组抗S抗原抗体平均增幅32.7倍,同源BBIBP-CorV组为2.6倍,差异显著(p<0.0001)。
  • 异源组中和抗体平均增幅3.4倍,同源组1.8倍,差异显著(p<0.0001)。
  • 异源组非严重不良事件(注射部位疼痛、发热、乏力)更常见,但无严重不良事件发生。

核心结论

  • 在已完成两剂灭活BBIBP-CorV基础免疫者中,异源BNT162b2加强接种较同源BBIBP-CorV加强接种对SARS-CoV-2产生更强的免疫应答,且看似安全且耐受良好。

研究设计与样本

  • 非随机、非盲II期观察性社区试验,在巴林开展。
  • 305名既往完成两剂BBIBP-CorV基础免疫的参与者入组,其中BBIBP-CorV同源加强组152人、BNT162b2异源加强组153人;最终分析纳入246人(BBIBP-CorV组127人、BNT162b2组119人)。
  • 免疫原性通过基线及第8周血清学状态判定;反应原性数据(安全性和不良事件)在整个研究期间收集,并结合参与者主导的电子日志。

主要发现

  • 两组加强接种后抗SARS-CoV-2抗体水平均显著升高。
  • 异源BNT162b2组抗S抗原特异性抗体平均增幅为32.7倍,同源BBIBP-CorV组为2.6倍,差异显著(p<0.0001)。
  • 异源BNT162b2组sVNT中和抗体平均增幅为3.4倍,同源BBIBP-CorV组为1.8倍,差异显著(p<0.0001)。
  • 同源BBIBP-CorV组抗N抗原特异性抗体水平显著升高(平均增幅3.8倍),异源BNT162b2组无升高。
  • 非严重不良事件(注射部位疼痛、发热、乏力)在异源BNT162b2组更常见报告,但未发生严重不良事件。

临床怎么用

  • 原文结论认为异源BNT162b2加强接种在BBIBP-CorV基础免疫者中较同源BBIBP-CorV加强接种产生更强免疫应答,且看似安全且耐受良好。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Booster vaccine doses against SARS-CoV-2 have been advocated to address evidence of waning immunity, breakthrough infection, and the emergence of immune-evasive variants. A heterologous prime-boost vaccine strategy may offer advantages over a homologous approach, but the safety and efficacy of this approach with the mRNA vaccine BNT162b2 (BNT: Pfizer) and inactivated BBIBP-CorV (BBIBT: Sinopharm) vaccines have not been studied. METHODS: We conducted a non-randomized, non-blinded phase II observational community trial acrossBahrain, investigating the reactogenic and immunogenic responseof participants who had previously received two doses of BBIBP, followed by a third booster dose of either BBIBP (homologous booster) or BNT (heterologous booster). Immunogenicity through serological statuswas determined at baseline and on the following 8thweek. Reactogenicity data (safety and adverse events) were collected throughout study period, in addition to participant-led electronic journaling. RESULTS: 305 participants (152 BBIBP and 153 BNT booster) were enrolled in the study,with 246 (127 BBIBP and 119 BNT booster) included in the final analysis. There was a significant increase in anti-SARS-CoV-2 antibody levels post booster administration in both groups; however, the heterologous BNT arm demonstrated a significantly larger mean increase in the level of spike (S) antigen-specific antibodies (32.7-fold increase versus 2.6, p < 0.0001) and sVNT neutralising antibodies (3.4-fold increase versus 1.8, p < 0.0001), whereas the homologous arm demonstrated a significant increase in the levels of nucleocapsid (N) antigen-specific antibodies (3.8-fold increase versus none). Non-serious adverse events (injection site pain, fever, and fatigue) were more commonly reported in the heterologous arm, but no serious adverse events occurred. CONCLUSION: Heterologous prime-boost vaccination with the mRNA BNT162b2 (Pfizer) vaccine in those who had received two doses of inactivated virus BBIBP-CorV (Sinopharm) vaccine demonstrated a more robust immune response against SARS-CoV-2 than the homologous BBIBP booster and appears safe and well tolerated. Clinical Trial Registry Number (ClinicalTrials.gov): NCT04993560.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Mallah SI, Alawadhi A, Jawad J, et al. Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals. Vaccine. 2023. PMID: 36725431. doi:10.1016/j.vaccine.2023.01.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。